BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $253,083 | +0.0% | 4,965 | +5.8% | 0.03% | -11.4% |
| Q3 2022 | $253,000 | -17.6% | 4,694 | -1.8% | 0.04% | -12.5% |
| Q2 2022 | $307,000 | -12.5% | 4,782 | +5.6% | 0.04% | 0.0% |
| Q1 2022 | $351,000 | -14.8% | 4,529 | -5.7% | 0.04% | -16.7% |
| Q4 2021 | $412,000 | +33.8% | 4,804 | +25.6% | 0.05% | +20.0% |
| Q3 2021 | $308,000 | 0.0% | 3,824 | 0.0% | 0.04% | -7.0% |
| Q2 2021 | $308,000 | -6.1% | 3,824 | -1.5% | 0.04% | -21.8% |
| Q1 2021 | $328,000 | +10.1% | 3,884 | +4.5% | 0.06% | -3.5% |
| Q4 2020 | $298,000 | +8.4% | 3,718 | +8.6% | 0.06% | -9.5% |
| Q3 2020 | $275,000 | -2.1% | 3,423 | +4.7% | 0.06% | -8.7% |
| Q2 2020 | $281,000 | +16.6% | 3,268 | +9.9% | 0.07% | -4.2% |
| Q1 2020 | $241,000 | -1.6% | 2,973 | +1.5% | 0.07% | +20.0% |
| Q4 2019 | $245,000 | -3.5% | 2,928 | +1.0% | 0.06% | -15.5% |
| Q3 2019 | $254,000 | +9.0% | 2,900 | +1.8% | 0.07% | +6.0% |
| Q2 2019 | $233,000 | -6.0% | 2,850 | -6.7% | 0.07% | 0.0% |
| Q1 2019 | $248,000 | +19.8% | 3,056 | +13.6% | 0.07% | +31.4% |
| Q3 2018 | $207,000 | -15.2% | 2,691 | -18.6% | 0.05% | -13.6% |
| Q2 2018 | $244,000 | +14.6% | 3,305 | +1.1% | 0.06% | +15.7% |
| Q1 2018 | $213,000 | +1.9% | 3,270 | +1.3% | 0.05% | +2.0% |
| Q4 2017 | $209,000 | – | 3,228 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |